|
About TAXOTERE Taxotere is currently approved in 4 different indications: In Breast Cancer In the United States and in Europe, Taxotere is approved to treat patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. It is also approved in Europe in combination with doxorubicine for patients who have received prior cytotoxic therapy for this condition and in combination with capecitabine after failure of cytotoxic therapy which would have included anthracycline. In the adjuvant setting post surgery ; it is approved in the US and in Europe in combination with doxorubicin and cyclophosphamide TAC regimen ; for the treatment of patients with operable, node-positive breast cancer. Finally, in Europe, Taxotere is approved in combination with trastuzumab for the treatment of patients with metastatic breast cancer- overexpressing Her2 receptor. In Lung Cancer In the US and in Europe, Taxotere, in combination with cisplatin, is approved for the treatment of patients with unresectable locally advanced or metastatic non-small cell lung cancer NSCLC ; who have not received prior chemotherapy, and it is also approved as a single agent, for patients with unresectable locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy. In Prostate cancer Taxotere is approved for use in combination with prednisone as a treatment for androgenindependent hormone-refractory ; metastatic prostate cancer in the US and in Europe. In Gastric Stomach ; cancer The FDA and the Committee for Medicinal Products for Human Use CHMP ; of the European Agency for the Evaluation of Medicinal Products EMEA ; approved in march 2005, the use of TAXOTERE Injection Concentrate in combination with cisplatin and 5-fluorouracil for the treatment of patients with advanced stomach gastric ; cancer, including cancer of the gastro oesophageal junction, who have not received prior chemotherapy for advanced disease.
1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8: 1777-1781, 1990 Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4: 400-407, 1986 International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers: International Germ Cell Cancer Collaborative Group. J Clin Oncol 15: 594603, 1997 Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163-1172, 1991 Bower M, Newlands ES, Holden L, et al: Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB ACE chemotherapy. Ann Oncol 8: 477-483, 1997 Kaye SB, Mead GM, Fossa SD, et al: Intensive inductionsequential chemotherapy with BOP VIP-B compared with treatment with BEP EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692-701, 1998 Culine S, Theodore C, Bekradda M, et al: Experience with bleomycin, etoposide, cisplatin BEP ; and alternating cisplatin, cyclophosphamide, doxorubicin CISCA II vinblastine, bleomycin VB IV regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. J Clin Oncol 20: 184-188, 1997 de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 13111314, 1995 Motzer RJ, Mazumdar M, Bajorin DF, et al: High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15: 2546-2552, 1997 Bokemeyer C, Harstrick A., Beyer J, et al: High-dose HD ; VIP-chemotherapy CTX ; plus peripheral stem cell PBSC ; support as first-line therapy for advanced germ cell cancer. Proc Soc Clin Oncol 17: 326a, 1998 abstr 1258 ; 11. Chevreau C, Droz JP, Pico JL, et al: Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours: Preliminary results of a French randomized trial. Eur Urol 23: 213-217, 1993 Bokemeyer C, Harstrick A, Beyer J, et al: The use of doseintensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors: German Testicular Cancer Study Group. Semin Oncol 25: 24-32, 1998 Nichols CR, Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 16: 1287-1293, 1998 Cox DR, Oakes D: Analysis of survival data. London, United Kingdom, Chapman & Hall, 1984 15. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Stat Assoc 53: 457-481, 1958 Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85: 1828-1835, 1993 Bajorin DF, Mazumdar M, Meyers M, et al: Metastatic germ cell tumors: Modeling for response to chemotherapy. J Clin Oncol 16: 707715, 1998 Saxman SB, Finch D, Gonin R, et al: Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 16: 702-706, 1998 Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stemcell transplantation in relapsed or refractory germ cell cancer: A phase I II study. J Clin Oncol 12: 1223-1231, 1994 Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14: 1098-1105, 1996 Pedersen BJ, Daugaard G, Hansen SW, et al: Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338: 359-363, 1991 Boshoff C, Begent RH, Oliver RT, et al: Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 6: 35-40, 1995 Kollmannsberger C, Beyer J, Droz JP, et al: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16: 3386-3391, 1998 Nichols CR, Breeden ES, Loehrer PJ, et al: Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 85: 36-40, 1993 Bajorin DF, Motzer RJ, Rodriguez E, et al: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposidecontaining chemotherapy. J Natl Cancer Inst 85: 60-62, 1993 Bokemeyer C, Schmoll HJ: Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11: 1703-1709, 1993.
Doxorubicin children
1. Berzon R, Hays RD.Shumaker SA. International use, application and performance of health related quality of life measurements. Qual Life Res 1993; 2: 367-9. Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evalualiong cross-cultural instruments from minimum requirements to optimal models. Qual Life Res 1993; 2: 451-9. Cella DF, Wiklund I, Shumaker SA, Aaronson NK. Integrating health related quality of life into cross national clinical trials. Qual Life Res 1993; 2: 443. Guillemin F, Bombardier C, Beatin D. Cross-cultural adaptation of health related quality of life measures, literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-32. Anderson RT, McFarlane M, Naughton MJ, Shumaker SA. Conceptual issues and considerations in cross cultural validation of generic health related quality of life instruments. In Spilker B ed ; : Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven 1996. 6. Schag CAC, Heinrich RL. Development of a comprehensive quality of life measurement tool: CARES. Oncology 1990; 4: 135-8. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organisation for research and Treatment of Cancer QLQ C-30: A quality of life instrument for use in international clinical trials in oncology. J Nat! Cancer Inst 1993; 85: 365-76. Cella DF, Tulsky DS, Gray G. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-9. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the the quality of life of cancer patients. The Functional Living IndexCancer: The development and validation. J Clin Oncol 1984; 2: 472. Levine MN, Guyatt GH, Gent M. Quality of life in stage II breast cancer, an instrument for clinical trials. J Clin Oncol 1988; 6: 1798-810. Watson M, Law M, Maguire P et al. Further development of a quality of life measure for cancer patients: The Rotterdam Symptom Checklist revised ; . Psycho-Oncol 1992; 1: 35-44. Hopwood P, Howell A, Maguire P. Screening for psychiatric morbidity in patients with advanced breast cancer: Validation of two self-report questionnaires. Br J Cancer 1991; 64: 353-6. Ibbotson T. Maguire P, Selby P et al. Screening for anxiety and depression in cancer patients -- the effects of disease and treatment. Eur J Cancer 1994; 64: 349-52. Luteijn F, Kok AR, Hamel LF, Poiesz A. Enige ervaringen met een klachtenlijst. Ned Tijdschr Psychol 1979; 34: 167-79. Linssen ACG, Van Dam FSAM, Engelsman E et al. Leven met cytostatica Living with cytostatic drugs ; . Pharmaceut Weekbl 1979; 114: 501-15. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 1978; 373-80. 17. De Haes JGIM, Van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034-8. Paci E. Assessment of valildity and clinical application of an italian version of the Rotterdam Symptom Ckecklist. Qual Life Res 1992; I: 129-34. 19. Varela Y. Spanish version of the Rotterdam Symptom Checklist: 20. Cross-cultural adaptation and preliminary validation in a sample of terminal cancer patients. Psycho-Oncol 1998 in press ; . De Haes JCJM. Kwaliteit van leven van kankerpatienten [Quality of life of cancer patients]. Thesis. Amsterdam Lisse: Rijksuniversiteit Leiden, Swets & Zcitlinger 1988. Richards MA, Hopwood P, Ramirez AJ et al. Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality oflife. Eur J Cancer 1992; 28A: 1023-8. Soukop M, McQuade B, Hunter E. Ondansetron compared with metoclopramide in the control of emesis and quality oflife during repeated chemotherapy for breast cancer. Oncology 1992; 49: 295-304. Maguire P, Selby P. Assessing quality oflife in cancer patients. Br J Cancer 1989; 60: 437 0. Uyl-De Groot CA, Rutten FH, Bonsel GJ. Measurement and valuation of quality oflife in economic appraisal of cancer treatment. Eur J Cancer 1994; 30a: 111-7. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15, Editorial. Adjuvant systemic therapy for early breast cancer. Lancet 1992; 339: 27. Editorial. Ovarian ablation in early breast cancer: Phoenix arisen? Lancet 1992; 339: 95. De Haes JCJM, De Ruiter JH, Tempelaar R. Pennink BJW. The distinction between affect and cognition in the quality of life of cancer patients - sensitivity and stability. Qual Life Res 1992; 1: 315-22. Tempelaar R, De Haes JCJM, De Ruiter JH ct al. The social experiences of cancer patients under treatment. Soc Sci Med 1989; 29: 635 t2. Nunnally JC. Psychometric Theory. New York: McGraw Hill 1978. SAS Institute Inc.'SAS STAT User's Guide, Version 6, Vols. 1 and 2. Cary, NC: SAS Institute Inc. 1990. Sadura A, Pater J, Osoba D et al. Quality of life assessment: Patient compliance with questionnaire completion. J Natl Cancer Insl 1992; 84: 1023-6. Bernhard J, Hurny DTH, Coates A, Gelber RD. Applying quality of life principles in international cancer clinical trials. In Spilker B ed ; : Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven 1996. Hurny C, Bernhard J, Gelber RD et al. Quality of life measurements for patients receiving adjuvant therapy for breast cancer: An international trial. Eur J Cancer 1992; 28: 118-24. Collings JA. International differences in psychosocial well-being: A comparative study of adults with epilepsy in three countries. Seizure 1994; 3: 183-90.
Doxorubicin picture
Another form of doxorubicin cardiotoxicity is arrhythmia which may occur at any time and after any dosage.
Casciari, J.J., Sotirchos, S.V., Sutherland, R.M., 1998. Glucose diffusivity in multicellular tumor spheroids. Cancer Res. 48, 39053909. Cojocaru, L., Agur, Z., 1992. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math. Biosci. 109, 8597. Couderc, B., Dujols, J.P., Mokhtari, F., Norkowski, J.L., Slawinski, J.C., Schlaifer, D., 2000. The management of adult aggressive non-Hodgkin's lymphomas. Crit. Rev. Oncol. Hematol. 35, 3348. Crone, C., Levitt, D.G., 1984. Handbook of Physiology: A Critical, Comprehensive Presentation of Physiological Knowledge and Concepts. American Physiological Society, Bethesda, ML. Deutsch, A., Dormann, S., 2002. Modeling of avascular tumor growth with a hybrid cellular automaton. In Silico Biol. 2, 114. Enden, G, Popel, A.S., 1994. A numerical study of plasma skimming in small vascular bifurcations. J. Biomech. Eng. 116, 7988. Erlanson, M., Lindth, J., Zackrisson, B., Landberg, G., Roos, G., 1995. Cell kinetic analysis of non-Hodgkin's lymphomas using in vivo Iodeoxyuridine incorporation and flow cytometry. Hematol. Oncol. 13, 207217. Hackbusch, W., 1985. Multigrid Methods and Applications. Springer, Berlin. Hardman, J.G., Limbird, L.E., Gilman, A.G., 2001. The Pharmacological Basis of Therapeutics. McGraw-Hill Companies. Honda, H., Yoshizato, K., 1997. Formation of branching pattern of blood vessels in the wall of the avian yolk sac studied by computer simulation. Dev. Growth Differ. 39, 581589. Jain, R.K., 2001. Delivery of molecular and cellular medicine to solid tumours. Adv. Drug. Deliv. Rev. 46, 146168. Konerding, M.A., Fait, E., Gaumann, A., 2001. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br. J. Cancer. 84, 13541362. Kwok, T.T., Twentyman, P.R., 1985. The response to cytotoxic drugs of EMT6 cells treated either as intact or disaggregated spheroid. Br. J. Cancer. 51, 211218. Lankelma, J., Luque, R.F., Dekker, H., Schinkel, W., Pinedo, H., 2000. A mathematical model of drug transport in human breast cancer. Microvasc. Res. 59, 149161. Lapela, M., Leskinen, S., Minn, H.R., Lindholm, P., Klemi, P.J., Soderstrom, K.O., Bergman, J., Haaparanta, M., Ruotsalainen, U., Solin, O., 1995. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-19-fluorodeoxyglucose. Blood 1 86, 35223527. Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., Morel, P., Herbrecht, R., Reyes, F., Coiffier, B., 1993. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. Groupe d'Etude des Lymphomes de l'Adulte ; . Ann. Oncol. 4, 651656. Liotta, L.A., Saidel, G.M., Kleinerman, J., 1977. Diffusion model of tumor vascularization and growth. Bull. Math. Biol. 39, 117128. McCormick, S.F., 1987. Multigrid Methods. SIAM, Philadelphia. McDougall, S.R., Anderson, A.R.A., Chaplain, M.A.J., Sherratt, J.A., 2002. Mathematical modelling of flow through vascular networks: Implications for tumour-induced angiogenesis and chemotherapy strategies. Bull. Math. Biol. 64, 673702. Nagai, K., Nagasawa, K., Sadzuka, Y., Tsujimoto, M., Takara, K., Ohnishi, N., Yokoyama, T., Fujimoto, S., 2002. Relationships between the in vitro cytotoxicity and transport characteristics of Pirarubicin and Doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother. Pharmacol. 49, 244250. Orme, M.E., Chaplain, M.A.J., 1996. A mathematical model of vascular tumour growth and invasion. Math. Comput. Modelling 23, 4360. Patel, A.A., Gawlinski, E.T., Lemieux, S.K., Gatenby, R.A., 2001. A cellular automaton model of early tumor growth and invasion. J. Theor. Biol. 7 213, 315331. Pries, A.R., Secomb, T.W., Gaehtgens, P., 1998. Structural adaptation and stability of microvascular networks: theory and simulations. Am. J. Physiol. 275, H349H360. Pries, A.R., Secomb, T.W., Gessner, T., Sperandio, M.B., Gross, J.F., Gaehtgens, P., 1994. Resistance to blood flow in microvessels in vivo. Circ. Res. 75, 904915. Stokke, T., Holte, H., Smedshammer, L., Smeland, E.B., Kaalhus, O., Steen, H.B., 1998. Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas. Br. J. Cancer 77, 18321838.
Doxorubicin nephrotoxicity
108 Further evidence supporting our hypothesis was drome, or simply a newly recognized syndrome. The provided by two reports from St. Jude by Pui et al. [16, epipodophyllotoxins are relatively new agents, and 17]. This group's initial report [16] suggested that pa- probably account for most of the reported cases. Howtients with a T-cell acute lymphoid leukemia who ever, it appears that other commonly used intercalating received teniposide ; were at especially high risk, al- agents, such as doxorubicin and actinomycin D, are though both of their reports are consistent with the also leukemogenic. Doxorubicin is almost always given hypothesis that epipodophyllotoxins are leukemogenic. in combination with alkylating agents such as cycloEight of these thirteen cases included abnormalities, phosphamide. Thus, it would be difficult to distinguish primarily balanced translocations, involving Ilq23. a doxorubicin-induced leukemia with a balanced Most of these cases had monoblastic features, and oc- translocation ; from cyclophosphamide-induced leukecurred with a relatively short latent period as described mia with abnormalities of chromosome 5 and or 7 or our initial report. an unbalanced translocation ; without careful cytogeMost recently, Pedersen-Bjergaard et al. reported netic analysis, often not available to most clinicians. In five patients with AML after etoposide, cisplatin and fact, there are examples in the literature of patients bleomycin for germ-cell tumors [18]. The risk of treated with alkylating agents plus other topoisomerase leukemia was related to total etoposide dose. Two cases II inhibitors, such as actinomycin D [31, 32], amsacrine had monocytoid features, and one case had a typical [31], doxorubicin [32, 33], and mitoxantrone [34], who t 9; ll ; . interest, two cases had a t 8; 21 ; , abnor- developed secondary leukemias similar to those cases mality usually seen with de novo AML M2. attributed to epipodophyllotoxins. Further indirect evidence is provided by Kaldor et al. [13] who noted that There have also been a number of case reports or series including one or more patients similar to our the risk of secondary leukemia after treatment for ovaroriginal description [19-28]. This body of literature ian cancer with doxorubicin and cisplatin was comparconvincingly demonstrates an association between able to that of cyclophosphamide at a high cumulative prior epipodophyllotoxin therapy and subsequent dose. development of a monoblastic leukemia with abnormalities of Ilq23. There is also a suggestion that other intercalating agents acting via topoisomerase II inhibi- Clastogenic effects of chemotherapcutic agents tion may also be leukemogenic [24, 29], and that this class of drugs may induce other balanced transloca- Carcinogenic effects of cytotoxic agents can be due to tions as well [17, 18, 30]. direct damage to DNA or to DNA cleavage in associaPedersen-Bjergaard and Philip recently addressed tion with topoisomerase II inhibitors and induction of this issue by reanalyzing 91 of their cases [29]. They sister chromatid exchanges SCE ; and other chromocorrelated the prior treatment with the type of aberra- somal aberrations clastogenesis ; . Whereas alkylating tion involving 21q22 as well as Uq23, dividing patients agents, by definition, bind directly to DNA, both interinto groups with balanced versus unbalanced transloca- calating agents and epipodophyllotoxins are clastogentions. All six t-AML cases with balanced Ilq23 trans- ic [35-41]. locations had been previously treated with etoposide; There is strong evidence to support the hypothesis four of them were also treated with multiple drugs that action of DNA topoisomerases, particularly topoincluding CCNU, cyclophosphamide, doxorubicin, and isomerase II, is required for the development of SCE 5-fluorouracil. All five patients with 21q22 balanced [42]. Topoisomerase I incises a single DNA strand, with translocations had also received topoisomerase II inhi- resultant binding to the 3' end. In contrast, topoisobitors. Of six patients with unbalanced translocations, merase II, a dimeric protein, produces double-strand none had received only topoisomerase II inhibitors. breaks with binding to each of the 3' ends, leaving the 5' Although three patients had received these agents at ends free. These topoisomerases thus allow for the some time, five of the six had also received alkylating unwinding of DNA, and are thought to be important for agents. Among 56 patients who had not received topo- efficient DNA replication. isomerase II inhibitors, none had balanced translocaSeveral models have been proposed for the formations involving these two bands. Among our own series tion of SCE [42]. All of these models require DNA of more than 120 patients, eight of ten with balanced incision, followed by DNA-topoisomerase binding. translocations had received topoisomerase II inhibitors There is no clear conclusion as to the final event in six of them in conjunction with alkylating agents ; SCE induction, with evidence for both exchange of [R. A. Larson and J. D. Rowley, unpublished]. In con- topoisomerase II subunits [37] and strand switching trast, only one of ten with unbalanced translocations during removal of parental helical turns by topoisohad received a topoisomerase II inhibitor, thus con- merases [43, 44]. firming the observation of Pedersen-Bjergaard and Inhibitors of topoisomerase II include both the Philip that topoisomerase II inhibitors are associated intercalators [45] and non-intercalating epipodophylwith balanced but not unbalanced translocations of lotoxins [46]. These agents inhibit the ligase activity of these two chromosome bands. topoisomerase n, thereby resulting in protein-associIt is appropriate to ask whether this is a new syn- ated double-strand DNA breaks, as well as SCE. Of and dronabinol.
Doxorubicin emission fluorescence
Premedication consisting of analgesia and an antihistamine should always be administered before each infusion of Rituximab. e.g. paracetamol and chlorphenamine ; Occurrence of an Infusion Related Event or Hypersensitivity: Stop the infusion and contact a doctor When symptoms improve, continue the infusion at half the rate prior to the reaction Accelerate the infusion rate more slowly as tolerated by the patient Use rituximab rate calculator to assist with rate escalation of rituximab infusion Rituximab doses should be rounded to the nearest 100mg Dose modifications Renal function GFR ml min ; Etoposide Dose 50 Full dose 10-50 75% of dose 10 50% of dose Hepatic function Bilirubin % of full dose 1-2 x ULN Reduce doxorubicin dose to 50% dose Reduce vincristine dose to 50% dose Reduce etoposide dose to 50% dose 2-4 x ULN Reduce doxorubicin dose to 25% dose Reduce vincristine dose to 25% dose Reduce etoposide dose to 25% dose 4 x ULN Omit doxorubicin & etoposide Neurotoxicity If neurotoxicity of grade 2 or greater severity occurs, consider omitting vincristine
Signs of cardiomyopathy, and there was 1 instance of ascites. These findings were not evaluated quantitatively. Mean heart weights were similar 0.18 0.5 g in treated mice versus 0.18 0.4 g in controls ; and not statistically different. However, mean COX-2 protein expression was higher in untreated controls than in the COX-2 inhibitortreated mice 6442 1635 versus 4300 2408 arbitrary units; P 0.022; Figure 4 ; . In the 5 mice that received neither doxorubicin nor COX-2 inhibitor, there were no deaths or abnormal pathological findings, and in the 5 that received only the COX-2 inhibitor, there was 1 death and no abnormal pathological findings and dss.
Related drugs by class antimetabolites methotrexate , hydroxyurea , hydrea , dacogen , cytarabine , alimta by condition acute lymphoblastic leukemia methotrexate , gleevec , doxorubicin , imatinib , adriamycin , nelarabine , more.
Michael phillipssaturday january 12, 200 guardian unlimited ; epo prevents chemotherapy cardiotoxicity, study suggests dec 27, 2007 26, ; researchers at the university of grenoble, in france, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures and dulcolax!
MOL 16519 clusterin was not expressed in MCF-7 cells before or after doxorubicin treatment Figure 5B, lanes 1 and 2 ; but was efficiently induced by doxorubicin in both MDA-MB-231 and HeLa cells Fig. 5B, lanes 3-6 ; . Like CAII, Id2 was expressed highly in MCF-7 cells Fig. 5C, lane 3 ; , and its expression did not increase after doxorubicin treatment Fig. 5C, lane 4 ; . Similar to clusterin, p55PIK was expressed at low levels in MCF-7 cells Fig. 5D, lane 3 ; , and p55PIK expression decreased in MCF-7 cells after doxorubicin treatment Fig. 5D, lane 4 ; . The only gene with a similar regulation in MDA-MB-231 and MCF-7 cells was Atf3, which was minimally expressed in both cell lines Fig. 5E, lanes 1 and 3 ; and was induced by doxorubicin Fig. 5E, lanes 2 and 4 ; . CAII, Id2, Atf3, and clusterin regulate drug susceptibility. To determine the roles of doxorubicin-induced genes, we attenuated the expression of several genes using RNAi oligonucleotide duplexes Elbashir et al., 2001 ; . CAII, Id2, and clusterin expression was inhibited by transiently transfecting MDA-MB-231 cells with RNAi duplexes targeting the genes CAIIi, Id2i, or CLSi ; or with a non-specific control sequence con, Fig. 6 ; . RNAi molecules targeting CAII, Id2, and clusterin inhibited the basal expression of Id2 Fig. 6B, compare lanes 1 and 3 ; or attenuated the induction of each gene after doxorubicin treatment Fig. 6A-C, compare lanes 2 and 4 ; . Furthermore, CAII protein levels were markedly decreased before Figure 6D, lanes 1 and 2 ; and after doxorubicin treatment Figure 6D, lanes 3 and 4 ; in CAIIi-transfected cells. Cells with inhibited clusterin expression exhibited a loss of viability compared to controltransfected cells following doxorubicin treatment Figure 7A ; . The change in viability in CLSivs. control-transfected cells at 0.08-2 M doxorubicin was significant P 0.007 for each dose ; . There was no change in viability in CLSi-transfected cells without drug treatment, consistent.
Doxorubicin half life
Al, 40-44 for example, performed a series of small trials in which patients with inoperable but localized tumors received either chemotherapy alone or chemotherapy plus radiation. Among other agents, bleomycin and doxorubicin were used singly and in combination. In each study, the response rate for combined-modality therapy was superior to that for chemotherapy alone, but only a slight increase in survival was noted. The Eastern Cooperative Oncology Group ECOG ; performed a phase 3 trial45 using bleomycin with concurrent radiation vs radiation alone and reported no difference in survival outcome. Byfield and colleagues46 conducted the first trial of continuous-infusion 5-FU used as a radiosensitizer with concurrent radiotherapy in unresectable esophageal cancer, with clinical CRs seen in the small series of patients. Coia et a147 reviewed the experience at Fox Chase Cancer Center over a 10-year period in 57 patients given two cycles of continuous-infusion 5-FU and mitomycin concurrently with high-dose radiotherapy 6, 000 cGy over 6 to 7 weeks ; . Median survival was 18 months, and 18% of patients survived 5 years. Local control was obtained in 70% of patients. Eventually, local failure occurred in 48% of patients and duragesic.
Figure 2. NPT-II activity in rice protoplasts electroporated with different chimeric constructs. Protoplasts were electroporated with equimolar amounts of plasmid DNA carrying the different chimeric constructs. After a 48-h culture period, proteins were isolated from the protoplasts and equal amounts of proteins were subjected to an NPT-II assay. Shorter exposures of the autoradiogram, suitable for visualizing 2'-npt-11, show no cross-contamination of samples in adjacent lanes. The kanamycin-32P04 spots were quantified 23 ; and normalized to the activity produced by the 2'-npt-11 construct. The asterisk designates an electroporation with pGVL1 50 containing a promoterless npt-ll gene.
Doxorubicin toxicity treatment
Extemporaneous preparations of ophthalmic antibiotics are often prescribed for the treatment of severe ocular infectious disease. Infectious keratitis is a potentially blinding condition caused by a variety of microorganisms. Frequent instillation of topical antimicrobial agents is the mainstay of treatment. The drug concentration in commercially available antimicrobial ophthalmic solutions is generally too low for adequate treatment, and solutions and echinacea.
One hypothesis of CDA-induced symptoms of rhinitis is that the respiratory mucosa of individuals with CDA sensitivity cannot compensate for the loss of water that occurs on exposure to the stimulus, leading to epithelial damage. Cruz et al found a 6-fold increase in nasal lavage epithelial cells in the CDA-sensitive group after CDA, but not after warm, moist air [39]. This finding shows that epithelial cell shedding accompanies clinical responses to CDA in the human nose, supporting the above hypothesis.
Doxorubicin dna adducts
Lowed by ; endocrine therapy were both considered appropriate treatment options. Data from individual clinical trials on the treatment of patients with node-negative disease indicate that the addition of classical CMF cyclophosphamide, 100 mg m2 orally, daily on days 1 through 14; methotrexate 40 mg m2 administered intravenously [IV] and fluorouracil 600 mg m2 IV, both on days 1 and 8, repeated every 4 weeks49 ; or of methotrexate followed by fluorouracil M-F ; to tamoxifen benefited the patients as compared with tamoxifen alone.70 Additional information from a trial conducted specifically in postmenopausal patients leads to the conclusion that much of the effect of chemotherapy three courses of classical CMF ; is seen in patients with low or no estrogen receptor expression in the primary tumor.71 The use of an adjuvant anthracycline-based regimen is probably indicated in the high-risk, node-negative setting. The choice of the regimen should especially account for the results from two trials in which classical CMF was compared with an anthracycline combination. In one trial, a CMF-like anthracycline regimen CAF, in which cyclophosphamide is given orally on days 1 through 14, and doxorubicin and fluorouracil, both IV, are given on days 1 and 8 of a 28-day course ; was shown to improve outcome when compared with and efalizumab.
| Doxorubicin pills
Doxorubicin ic50
Neuronitis vestibular neuritis, redux 326, xifaxan small bowel, aldactone searle and myofascial pain syndrome nih. Potassium deficiency bulimia, tuberculin vials, disseminated nocardia infection and social anxiety disorder eating or no sneeze kitties.
Doxorubicin extravasation
Dox9rubicin, doxorubicln, coxorubicin, dlxorubicin, doxorub8cin, doxorubiicn, doxorubicib, foxorubicin, soxorubicin, doxorybicin, dkxorubicin, doxoruubicin, doxoubicin, doxrubicin, doxorub9cin, docorubicin, doxoeubicin, doxorbicin, oxorubicin, dox0rubicin.
Doxorubicin dose response
Doxorubicin children, doxorubicin picture, doxorubicin nephrotoxicity, doxorubicin emission fluorescence and doxorubicin half life. Doxorubicin toxicity treatment, doxorubicin dna adducts, doxorubicin pills and doxorubicin ic50 or doxorubicin extravasation.
|
| |
|
